28. 全身性アミロイドーシス Systemic amyloidosis Clinical trials / Disease details


臨床試験数 : 261 薬物数 : 286 - (DrugBank : 81) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 177

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04754945
(ClinicalTrials.gov)
April 28, 20219/2/2021Isatuximab as Upfront Therapy for the Treatment of High Risk AL AmyloidosisSlow-Go Strategy for High Risk AL Amyloidosis: Isatuximab for Upfront TherapyAL AmyloidosisDrug: Bortezomib;Drug: Cyclophosphamide;Drug: Dexamethasone;Biological: IsatuximabEmory UniversitySanofi;National Cancer Institute (NCI)Recruiting18 YearsN/AAll25Phase 1United States
2NCT03499808
(ClinicalTrials.gov)
March 8, 20189/4/2018S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary AmyloidosisA Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients With Previously Treated AL AmyloidosisAmorphous, Eosinophilic, and Acellular Deposit;Constipation;Diarrhea;Early Satiety;Gastrointestinal Hemorrhage;Hepatomegaly;Lymphadenopathy;Macroglossia;Nausea;Primary Systemic Amyloidosis;Purpura;Recurrent Primary Amyloidosis;Refractory Primary AmyloidosisBiological: Isatuximab;Other: Laboratory Biomarker AnalysisSouthwest Oncology GroupNational Cancer Institute (NCI)Active, not recruiting18 YearsN/AAll43Phase 2United States